Belatacept and Long-Term Outcomes in Kidney Transplantation.

By F. Vincenti, L. Rostaing, J. Grinyo, K. Rice, S. Steinberg, L. Gaite, M. Moal, G. Mondragón-Ramírez, J. Kothari, M. Polinsky and 3 more. New England Journal of Medicine, 2016

709 citations recorded by the source corpus.

Subfields: Immunology, Surgery, Transplantation

View Paper: https://www.semanticscholar.org/paper/db4cf0ca22772fa6219d1512406f5d8adc40fc18

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Philip F. Halloran

In Surgery

1. Curtis Huttenhower
2. Philip F. Halloran
3. Dirk Gevers

In Transplantation

1. Philip F. Halloran

Citations in the corpus

• Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. (2016, background): “0000000000001268 I the January 28, 2016, issue of the New England Journal of Medicine, Vincenti et al reported on 7-year outcome results of the Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT) .(1) Previously, outcomes after 1, 2, 3, and 5 years ”
• The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials (2018, methodology): “lead to a higher rate of graft loss in the long-term as shown by the BENEFIT-EXT study [5,6].”